

RE: J&J Announces a Lead Vaccine Candidate for COVID-19

vendredi 28 mai 2021 16:38

| | |
|---------|--|
| Subject | RE: J&J Announces a Lead Vaccine Candidate for COVID-19 |
| From | RYAN John-F (SANTE) |
| To | [REDACTED] [JPPBE] |
| Cc | [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED] (SANTE); SANTE-DIRECTOR-C |
| Sent | jeudi 2 avril 2020 19:34 |

Dear Ms [REDACTED]

Thank you for this most interesting information from your side. We may contact you to discuss further in due course.

Best

[REDACTED]
Director



European Commission

Health and Food Safety Directorate General

Directorate C – Public Health and crisis management

HTC 03 [REDACTED]

L-2920 Luxembourg

[REDACTED]
Fax.: + 352 4301 [REDACTED]

From: [REDACTED] [JPPBE]

Sent: Thursday, April 2, 2020 6:17 PM

To: RYAN John-F (SANTE)

Subject: J&J Announces a Lead Vaccine Candidate for COVID-19

Good afternoon Mr Ryan

Please find the below message which Johnson & Johnson sent to Director General Anne Bucher and accept our sincerest apologies for any inconvenience caused to your colleague.

Thank you kindly.

Best regards,

From: [REDACTED] [JPPBE] <[REDACTED]@its.jnj.com>

Sent: donderdag 2 april 2020 9:33

To: SANTE-DIRECTOR-C@ec.europa.eu

Cc: [REDACTED] [JPPBE] <[REDACTED]@its.jnj.com>

Subject: RE: J&J Announces a Lead Vaccine Candidate for COVID-19

Thank you for acknowledging and we registered the request for adjusting the email address.

Thanks a lot

From: SANTE-DIRECTOR-C@ec.europa.eu <SANTE-DIRECTOR-C@ec.europa.eu>

Sent: Thursday, 2 April 2020 8:52 AM

To: [REDACTED] [JPPBE] <[REDACTED]@its.jnj.com>

Cc: [REDACTED] [JPPBE] <[REDACTED]@ITS.JNJ.com>; [REDACTED] [JPPBE]

<[REDACTED]@ITS.JNJ.com>; [REDACTED] [JPPBE] <[REDACTED]@ITS.JNJ.com>; [REDACTED]

like to share information with you regarding Johnson & Johnson's efforts to collaborate in the fight against COVID-19.

This 30th of March, Johnson & Johnson announced the selection of a [lead COVID-19 vaccine candidate](#).

We are moving swiftly toward human clinical trials of the lead vaccine candidate by [REDACTED] and we anticipate the first batches of a COVID-19 vaccine could be available for emergency use authorization in [REDACTED], a substantially accelerated timeframe. For comparison: the typical vaccine development process involves a number of different stages, ranging from 5 to 7 years before a candidate even qualifies for approval.

To upscale this effort, we have expanded our landmark partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and [REDACTED]. Together, we have committed [REDACTED] investment to co-fund vaccine research, development and clinical testing.

J&J will expand its manufacturing capacity to ensure global supply of more than one billion doses of a safe and effective vaccines worldwide. The Company plans to begin production at risk imminently and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use. The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.

We will also upscale Janssen's ongoing efforts to identify new or existing treatments. We are working with global partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising antiviral activity against the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV) that could contribute to providing immediate relief to the current outbreak. This work is being conducted in partnership with the [REDACTED]

This incredibly swift progress would not be possible without intense public-private collaboration. We still have a long way to go, but we are confident that this step marks a major milestone in ending COVID-19 for patients everywhere.

I also want to let you know how J&J is supporting frontline health workers, the backbone of our health systems and vital resources for global health security. Since the outbreak of the pandemic and with the rapidly evolving strain on health systems, we have mobilized to provide equipment, products, financial donations, and even our own human resources to support organizations and healthcare workers on the front lines. Our commitments include:

- A new global **volunteer leave policy** for medically trained J&J employees who are either called to serve or who volunteer to provide medical service support for the COVID-19 pandemic.
- Collaboration with the [redacted] government to increase the capacity of COVID-19 testing in [redacted] by offering testing capacity of our J&J laboratories in [redacted]. We are also producing disinfectant hand liquid in our industrial site in [redacted] to supply hospitals.
- [redacted] to the Johnson & Johnson Center for Health Worker Innovation to aid in the immediate COVID-19 response, primarily focused on supporting frontline health workers in the most affected-countries. Press release [here](#).
- [redacted] for The COVID-19 Solidarity Response Fund, which will enable individuals, and organizations around the world to directly support the World Health Organization's work to prevent, detect and respond to the COVID-19 pandemic (WHO).
- [redacted] financial donation to the [redacted].

Our team remains committed to these response efforts and available to answer any questions you may have, as we continue trying to live up to Our Promise to change the trajectory of health for humanity.


Please do not hesitate to reach out to us directly.

Sincerely,

[redacted]

Vice President Government Affairs & Policy, Europe, Middle East & Africa and

Johnson



Square de Meeûs 23, 5th floor
BE-1000 Brussels, Belgium